Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse

European Journal of Pharmacology

Volumn 454, Issue 1, 2002, Pages 95-102

  Mayer, Gaëll ^a   Taberner, Peter V ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Blood glucose; Efaroxan; Imidazoline; Insulin; KU14R; 2 Adrenoceptor

Indexed keywords

2 (2 IMIDAZOLIN 2 YL) 1,4 DIISOPROPYLPIPERAZINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDIABETIC AGENT; BENZOFURAN DERIVATIVE; BRIMONIDINE; DRUG RECEPTOR; EFAROXAN; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS; INSULIN; KU 14R; LIGAND; PIPERAZINE DERIVATIVE; QUINOXALINE DERIVATIVE; 2 (2 ETHYL 2,3 DIHYDROBENZO[B]FURAN 2 YL) 1H IMIDAZOLE; ADENOSINE TRIPHOSPHATE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; IMIDAZOLINE; POTASSIUM CHANNEL; POTASSIUM ION; RAUWOLSCINE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLOOD; CBA MOUSE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; ELECTROSTIMULATION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; IN VITRO STUDY; MALE; METABOLISM; MOUSE; PHYSIOLOGY; TIME; VAS DEFERENS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CELL ISOLATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; GLUCOSE HOMEOSTASIS; HYPOGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BENZOFURANS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN; LIGANDS; MALE; MICE; MICE, INBRED CBA; PIPERAZINES; QUINOXALINES; RECEPTORS, DRUG; TIME FACTORS; VAS DEFERENS;

EID: 0036842082     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02473-1     Document Type: Article

References (31)

1. Aguilar-Bryan L., Nichols C.G., Wechsler S.W., Clement J.P. IV, Boyd A.E. III, González G., Herrera-Sosa H., Nguy K., Bryan J., Nelson D.A. Cloning of the β cell high-affinity sulphonlyurea receptor: a regulator of insulin secretion. Nature. 268:1995;423-426.
2. Avellar M.C.W., Markus R.P. Are imidazoline receptors involved in sympathetic neurotransmission in rat vas deferens. Gen. Pharmacol. 27:1996;1273-1278.
3. Ball B.J., Flatt P.R., McClenaghan N.H. Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14R and RX801080. Pharmacol. Res. 42:2000;575-579.
4. Berdeu D., Puech R., Ribes G., Loubatrieres-Mariani M.M., Bertrand G. Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs. Eur. J. Pharmacol. 324:1997;233-239.
5. Berridge T.L., Doxey J.C., Roach A.G. Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats. Eur. J. Pharmacol. 213:1992;213-218.
6. Brown C.A., Loweth A.C., Smith S.A., Morgan N.G. Stimulation by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. Br. J. Pharmacol. 108:1993;312-317.
7. + channels in insulin secreting cells. Eur. J. Pharmacol. 204:1991;41-48.
8. 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. Eur. J. Pharmacol. 230:1993;375-378.
9. 2-sites. Br. J. Pharmacol. 112:1994;1065-1070.
10. Chan S.L.F., Pallett A.L., Clews J., Ramsden C.A., Morgan N.G. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with σ receptors. Eur. J. Pharmacol. 323:1997;241-244.
11. Chan S.F., Pallett A.L., Morgan N.G. Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;763-768.
12. Chan S.L.F., Pallett A.L., Clews J., Ramsden C.A., Chapman J.C., Kane C., Dunne M.J., Morgan N.G. Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites. Eur. J. Pharmacol. 355:1998;67-76.
13. ATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. Diabetes. 50:2001;340-347.
14. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., Dillon M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. TIPS. 19:1998;381-390.
15. Göthert M., Brüss M., Bönish H., Molderings G.J. Presynaptic imidazoline receptors, new development in characterization and classification. Ann. N.Y. Acad. Sci. 881:1999;171-184.
16. Hughes J., Kosterlitz H.W., Leslies F.M. Effect of morphine on adrenergic transmission in mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br. J. Pharmacol. 53:1975;371-381.
17. Langer J., Panten U., Zielmann S. Effects of α-adrenoceptor antagonists on clonidine-induced inhibition of insulin secretion by isolated pancreatic islets. Br. J. Pharmacol. 79:1983;415-420.
18. Le Brigand L., Virsolvy A., Manechez D., Godfroid J.J., Guardiola-Lemaitre B., Gribble F.M., Ashcroft F.M., Bataille D. In vitro mechanism of action on insulin release of S-22068, a new putative antidiabetic compound. Br. J. Pharmacol. 128:1999;1021-1026.
19. 2-Adrenoceptors modulating insulin release from isolated pancreatic islets. Naunyn-Schmiedeberg's Arch. Pharmacol. 313:1980;151-153.
20. Mayer G., Taberner P.V. Stimulation of insulin secretion in vivo by the imidazoline analogue KU14R. Br. J. Pharmacol. 134:2001;51.
21. Morgan N.G., Pallett A.L., Mourtada M., Chan S.L.F., Clews J., Ramsden C.A. Synthesis and characterisation of KU14R a novel antagonist of the pancreatic islet imidazoline binding site. Diabetologia. 39:1996;456.
22. Morgan N.G., Chan S.L.F., Mourtada M., Monks L.K., Ramsden C.A. Imidazolines and pancreatic hormone secretion. Ann. N.Y. Acad. Sci. 881:1999;217-228.
23. Pele-Tounian A., Wang X., Rondu F., Lamouri A., Touboul E., Marc S., Dokhan R., Pfeiffer B., Manechez D., Renard P., Guardiola-Lemaitre B., Godfroid J.J., Penicaud L., Ktorza A. Potent antihyperglycaemic property of a new imidazoline derivative S-22068 (PMS 847) in a rat model of NIDDM. Br. J. Pharmacol. 124:1998;1591-1596.
24. Pele-Tounian A., Chan S.L.F., Rondu F., Le Bihan G., Giroix M.-H., Lamouri A., Touboul E., Pfeiffer B., Manechez D., Renard P., Guardiola-Lemaitre B., Godfroid J.-J., Penicaud L., Morgan N.G., Ktorza A. Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. Eur. J. Pharmacol. 377:1999;81-87.
25. ATP channels is mediated by Kir6.2. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11716-11720.
26. Schulz A., Hasselblatt A. Dual action of clonidine on insulin release: suppression, but stimulation when α-adrenoceptors are blocked. Naunyn-Schmiedeberg's Arch. Pharmacol. 340:1989;712-714.
27. Slough S., Watkins J., Taberner P.V. Evidence for a functional pre-synaptic imidazoline receptor in the mouse isolated vas deferens. Br. J. Pharmacol. 131:2000;60.
28. 2-binding sites in rat brain membranes. Br. J. Pharmacol. 122:1997;66.
29. Wang X., Rondu F., Lamouri A., Dokhan R., Marc S., Touboul E., Pfeiffer B., Manechez D., Renard P., Guardiola-Lemaitre B., Godfroid J., Ktorza A., Penicaud L. Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J. Pharmacol. Exp. Ther. 278:1996;82-89.
30. Williams C.A., Shih M.-F., Taberner P.V. A simple acute in vivo comparative test for sensitivity to insulin in the mouse. Horm. Metab. Res. 31:1999;580-582.
31. Williams C.A., Shih M.-F., Taberner P.V. Effect of acute and sub-chronic administration of the imidazoline compound S 22068 on in vivo glucose and insulin responses in normal lean CBA/Ca mice. Gen. Pharmacol. 34:2000;183-191.